Airmid   Phone: (650) 368 6983


About us Overview  
  Board of directors :
    Michael Pennington
    Christine Beeton
    Spike Loy
    Drug Development Committee :
    Heike Wulff
    George Chandy
    Other Founders :
    Michael Cahalan
    Raymond Norton
    George Gutman
    Katalin Kalman
    Evan Gruber
Research and development Target Portfolio Unmet Needs
    AIRMID’s Novel Therapeutic Approach
    AIRMIDs Therapeutics
    Excellent Safety Profiles
    Proof-of-concept AIRMID Technology
  Key Publications  
  Development Strategies  
Autoimmune disease    
Multiple sclerosis    
Type 1 diabetes mellitus    
Kv1.3 Potassium Channel    
Effector memory T cells    


October 2016 Press Release on KPI Therapeutics Presenting Positive Data at Skin Disease Conference
June 2016
June 2016 Press Release About Promising Results of Dalazatide in Lupus Study
June 2016 Fact Sheet: What Is Lupus?
January 2016
January 2016 Press Release on KPI Biotech Showcase
January 2016 Board Member George Miljanich passes
December 2015
December 2015 AIRMID Makes Board Changes
November 2015
November 2015 New Lupus Treatment Being Tested for Younger Patients